Investor Presentaiton

Current regulatory requirements for viral shedding in Japan > We have no written document which shows regulatory requirements for viral shedding studies for gene therapy vectors in Japan. "Law Concerning the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of Living Modified Organisms " (Law No. 97 of 2003 ) Sponsor is required to prevent the transmission of vectors from patients to 3rd parties in clinical use of gene therapy products, according to the Cartagena Protocol on Biosafety (Type 1Use).

View entire presentation